Renaissance Group LLC Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Renaissance Group LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,596 shares of the company's stock, valued at approximately $1,908,000. Renaissance Group LLC owned approximately 0.09% of TransMedics Group at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Atlas Capital Advisors Inc. bought a new position in TransMedics Group in the fourth quarter valued at $31,000. Hager Investment Management Services LLC purchased a new stake in TransMedics Group in the fourth quarter worth approximately $33,000. Sachetta LLC bought a new position in TransMedics Group during the fourth quarter valued at approximately $40,000. AlphaQuest LLC purchased a new position in shares of TransMedics Group during the fourth quarter worth approximately $52,000. Finally, Quarry LP lifted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after acquiring an additional 312 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMDX. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $122.70.

Remove Ads

TransMedics Group Stock Up 4.7 %

Shares of NASDAQ TMDX traded up $3.80 during mid-day trading on Monday, hitting $84.38. 547,227 shares of the stock traded hands, compared to its average volume of 1,656,465. The stock has a fifty day moving average price of $70.94 and a 200-day moving average price of $81.18. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market cap of $2.84 billion, a price-to-earnings ratio of 89.77 and a beta of 2.14. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.